[HTML][HTML] Phase 3 trial of mRNA-1273 during the Delta-variant surge
LR Baden, HM El Sahly, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
LR Baden, HM El Sahly, B Essink, D Follmann, KM Neuzil, A August, H Clouting, G Fortier…
New England Journal of Medicine, 2021•Mass Medical SocmRNA-1273 Vaccine Efficacy against the Delta Variant Participants who had received
placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-
label phase. The incidence of Covid-19 in this group was lower than that in the group of
participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy
over time.
placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-
label phase. The incidence of Covid-19 in this group was lower than that in the group of
participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy
over time.
mRNA-1273 Vaccine Efficacy against the Delta Variant
Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than that in the group of participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy over time.
The New England Journal Of Medicine